Pyxis Oncology (PYXS) said Tuesday it will present new preclinical data from its phase 1 study of micvotabart pelidotin, antibody-drug conjugate to treat recurrent and metastatic head and neck squamous cell carcinoma, at the American Association for Cancer Research Meeting in Chicago in April.
In phase 1 trial, the drug showed monotherapy effect on multiple tumor types with significant tumor regression, according to the company. It has begun the part 2 monotherapy expansion cohorts of the ongoing Phase 1 to assess Micvo in second-line and third-line recurrent and metastatic head and neck squamous cell carcinoma patients who have received prior platinum and PD-1 inhibitor therapy and those who received prior EGFRi and PD-1 inhibitor therapy.
The company added that preliminary data for patients who received prior platinum and PD-1 inhibitor therapy are expected in H2. Preliminary data from those who received prior EGFRi and PD-1 inhibitor therapy are expected in H1 2026.
The company said it also started a phase 1/2 combination study of Micvo and Merck's anti-PD-1 therapy, Keytruda, in patients with R/M HNSCC and other solid tumors to identify the recommended Phase 2 dose by mid-2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。